氟达拉滨联合利妥昔单抗治疗高龄慢性淋巴细胞白血病

Effect of combined fludarabine and rituximab on chronic lymphocytic leukemia in old patients

  • 摘要: 目的 考察氟达拉滨联合治疗高龄慢性淋巴细胞白血病患者的有效性和安全性。方法 应用氟达拉滨联合利妥昔单抗方案治疗11例患者,根据患者情况分次给药,25~30mg/m2隔日或每周1~2次静脉注射,或口服剂型10mg~20mg/d连续用药,观察患者应用氟达拉滨过程中及其后的不良反应及疗效。结果 全组11例患者CR+PR为10例,其中CR6例,PR4例,NR1例。不良反应主要为粒细胞及血小板减少等骨髓抑制,未出现严重感染,无化疗相关死亡。结论 氟达拉滨联合利妥昔单抗治疗高龄慢性淋巴细胞白血病具有较高的安全性和有效性。

     

    Abstract: Objective To investigate the efficacy and safety of combined fludarabine and rituximab therapy for chronic lymphocytic leukemia in old patients. Methods Eleven old patients with chronic lymphocytic leukemia in our department were treated with combined fludarabine and rituximab(25-30mg/m2 every other day or 1-2 days per week by intravenous injection,or 10-20mg per day by oral administration).The adverse effects and efficacy of combined fludarabine and rituximab therapy were observed during and after the treatment. Results CR+PR was observed in 10 patients,and CR,PR,and NR were found in 6,4,and 1 patients,respectively.The main adverse effects occurred in the patients were leucocytopenia and thrombocytopenia.No severe infection and chemotherapy-related death occurred. Conclusion Combined fludarabine and rituximab therapy for chronic lymphocytic leukemia in old patients is rather effective and safe.

     

/

返回文章
返回